We conducted the most extensive Italian retrospective study to date, providing valuable insights into the comparative effectiveness of ZA and DMAB in combination with ET plus CDK4/6i, which represents the standard-of care therapy for patients with HR+/HER2-aBC. Here, CDK4 is linked to aneurysmal bone cyst.